Cerebrospinal Fluid and Clinical Profiles in Adult Type 2–3 Spinal Muscular Atrophy Patients Treated with Nusinersen: An 18-Month Single-Centre Experience

BACKGROUND AND OBJECTIVES: Nusinersen was approved as the first disease-modifying therapy in spinal muscular atrophy (SMA). Our aim was to analyse therapy-related changes in cerebrospinal fluid (CSF) and serum parameters of adult type 2–3 SMA and to correlate biochemical data with motor functional s...

Descripción completa

Detalles Bibliográficos
Autores principales: Milella, Giammarco, Introna, Alessandro, D’Errico, Eustachio, Fraddosio, Angela, Scaglione, Gaspare, Morea, Antonella, Ucci, Maria, Ruggieri, Maddalena, Mastrapasqua, Mariangela, Megna, Marisa, Puntillo, Filomena, Simone, Isabella Laura
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer International Publishing 2021
Materias:
Original Research Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8390404/
https://www.ncbi.nlm.nih.gov/pubmed/34389971
http://dx.doi.org/10.1007/s40261-021-01071-0

Ejemplares similares

Ejemplares similares